← Back to Screener
LENZ Therapeutics, Inc. Common Stock (LENZ)
Price$7.01
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-84.96%
Price vs S&P 500 (4W)-30.31%
VGM Score13.40
Market Capitalization$219.79M
All Metrics
Book Value / Share (Quarterly)$7.86
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.50
Price vs S&P 500 (YTD)-64.35%
Net Profit Margin (TTM)-519.30%
EPS (TTM)$-3.59
10-Day Avg Trading Volume0.70M
EPS Excl Extra (TTM)$-3.59
EPS (Annual)$-2.85
ROI (Annual)-28.88%
Gross Margin (Annual)97.81%
Cash / Share (Quarterly)$8.24
ROA (Last FY)-26.85%
EBITD / Share (TTM)$-3.96
ROE (5Y Avg)-34.74%
Operating Margin (TTM)-563.83%
Cash Flow / Share (Annual)$-2.23
P/B Ratio0.89x
P/B Ratio (Quarterly)1.16x
Net Income / Employee (Annual)$-540,300
Net Interest Coverage (TTM)-1708.25x
ROA (TTM)-34.80%
EPS Incl Extra (Annual)$-2.85
Current Ratio (Annual)14.23x
Quick Ratio (Quarterly)10.03x
3-Month Avg Trading Volume0.92M
52-Week Price Return-76.86%
Revenue / Employee (TTM)$138,100
P/S Ratio (Annual)11.51x
Asset Turnover (Annual)0.06x
52-Week High$50.40
EPS Excl Extra (Annual)$-2.85
CapEx CAGR (5Y)-11.81%
26-Week Price Return-77.03%
Quick Ratio (Annual)13.81x
13-Week Price Return-41.87%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.40x
Enterprise Value$195.02M
Revenue / Employee (Annual)$125,600
Pretax Margin (Annual)-427.62%
Cash / Share (Annual)$9.33
3-Month Return Std Dev84.53%
Net Income / Employee (TTM)$-717,100
ROE (Last FY)-28.88%
EPS Basic Excl Extra (Annual)$-2.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.59
ROI (TTM)-37.56%
P/S Ratio (TTM)10.47x
Revenue / Share (Annual)$0.66
Price vs S&P 500 (52W)-101.23%
Year-to-Date Return-56.19%
5-Day Price Return-5.78%
EPS Normalized (Annual)$-2.85
ROA (5Y Avg)-33.02%
Net Profit Margin (Annual)-430.25%
Month-to-Date Return-9.90%
EBITD / Share (Annual)$-3.15
Operating Margin (Annual)-477.46%
ROI (5Y Avg)-34.74%
EPS Basic Excl Extra (TTM)$-3.59
P/B Ratio (Annual)1.76x
Pretax Margin (TTM)-516.91%
Book Value / Share (Annual)$9.07
Price vs S&P 500 (13W)-50.13%
Beta2.00x
Revenue / Share (TTM)$0.67
ROE (TTM)-37.56%
52-Week Low$6.61
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-1.32est. -1.09
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.38
4.38
4.38
4.31
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LENZLENZ Therapeutics, Inc. Common Stock | — | — | F | $7.01 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
LENZ Therapeutics is a late-stage biopharmaceutical company developing ophthalmic treatments for presbyopia, the age-related loss of near vision affecting the majority of people over 45. The company is advancing therapies to address this widespread condition in a large and growing market.